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VAN EGERAAT C. and BREATHNACH P. The drivers of transnational subsidiary evolution: the upgrading of process R&D in the
Irish pharmaceutical industry, Regional Studies. This paper contributes to the theory of subsidiary evolution in large corporations
through an examination of the driving forces behind upgrading of process research and development (R&D) activities in the Irish
pharmaceutical industry. Drawing on a survey of pharmaceutical plants and interviews with transnational pharmaceutical plants, it
is shown that vigorous growth is occurring in the incidence of process R&D. The paper supports the utility of a multilevel systems
perspective on subsidiary evolution. The external environment, internal environment and subsidiary drivers are seen to drive
upgrading in a systemic way. The primary drivers for the subsidiaries’ enhanced role are located in the global external environment.
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文通过分析爱尔兰制药工业的工艺研发活动背后的驱动因素，对大公司分支机构的演化理论做出贡献。基于对制药
厂的问卷调查以及与跨国制药厂的访谈，研究发现工艺研发活动的增长强劲。本文认为分支机构演化的多层次系统
观是有用的。外部环境、内部环境以及分支机构驱动力通过一种系统的方法来推动升级活动。分支机构地位强化的
主要驱动力来自全球外部环境。
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VAN EGERAAT C. et BREATHNACH P. Les forces motrices de l’évolution des filiales transnationales: le renforcement de la R et D de
procédés dans l’industrie pharmaceutique irlandaise, Regional Studies. Cet article contribue à la théorie de l’évolution des filiales des
grandes sociétés à partir d’un examen des forces motrices qui sont à l’origine du renforcement des activités de recherche et dével-
oppement (R et D) de procédés dans l’industrie pharmaceutique irlandaise. Puisant dans une enquête des établissements pharmaceu-
tiques et des interviews auprès des établissements pharmaceutiques transnationaux, on montre que l’incidence de la R et D de
procédés à tendance à s’accroître vigoureusement. L’article voit l’évolution des filiales sous un jour systématique à plusieurs
niveaux. On considère que le milieu externe, le milieu interne et les forces motrices des filiales pilotent le renforcement d’une
manière systémique. Les principales forces motrices nécessaires au rôle accru des filiales sont à trouver dans le mileu mondial externe.
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Beitrag zur Theorie der subsidiären Evolution in Großbetrieben durch eine Untersuchung der treibenden Kräfte hinter einer Ver-
besserung der Aktivitäten zur Erforschung und Entwicklung von Verfahren in der irischen Pharmabranche. Anhand einer Erhe-
bung unter pharmazeutischen Betrieben und Interviews mit transnationalen pharmazeutischen Betrieben wird gezeigt, dass die
Inzidenz der Verfahrenserforschung und ‐entwicklung von starkem Wachstum geprägt ist. Der Beitrag liefert Argumente für
den Nutzen einer mehrschichtigen Systemperspektive der subsidiären Evolution. Die externe Umgebung, interne Umgebung
und subsidiären Faktoren werden als treibende Kräfte für eine Verbesserung auf systemische Weise betrachtet. Die primären trei-
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sociedades a través de un examen de los factores que impulsan mejoras en las actividades de la investigación y el desarrollo (I + D) de
procesos en la industria farmacéutica irlandesa. Basándonos en un estudio con plantas farmacéuticas y entrevistas con plantas farm-
acéuticas transnacionales, demostramos que está ocurriendo un fuerte crecimiento en la incidencia de la I + D de procesos. En este
artículo ofrecemos argumentos acerca de la utilidad de una perspectiva de sistema de varios niveles en lo que respecta a la evolución
subsidiaria. Consideramos que el entorno externo, el entorno interno y los factores subsidiarios estimulan las mejoras de modo
sistémico. Los factores principales para el papel mejorado de las subsidiaridades se sitúan en el entorno externo global.
Corporaciones transnacionales Evolución subsidiaria Investigación y Desarrollo (I + D) Industria farmacéutica Irlanda
JEL classifications: L52, L65, O14, O32
INTRODUCTION
This paper contributes to the theory of subsidiary evol-
ution within transnational corporations (TNCs), a
major growth area in research relating to TNCs. In par-
ticular, the paper interrogates key elements of this theory
through an empirical analysis of the driving forces behind
recent upgrading of process research and development
(R&D) activities in the Irish pharmaceutical industry.
By doing so, the paper addresses the need, identified
by BIRKINSHAW and HOOD (1998), for empirical
studies that can test the relevance of the increasing
number of theoretical models of subsidiary evolution.
The paper begins with a review of the recent literature
relating to subsidiary evolution, paying particular atten-
tion to the multilevel systems framework for analysing
subsidiary evolution proposed by TAVARES (2001).
This is followed, successively, by an account of the struc-
ture and organization of the R&D cycle within large
pharmaceutical firms and a description of the traditional
spatial configuration of this cycle. The next section
examines the recent growth in process R&D activities
in Irish pharmaceutical subsidiaries based on a compre-
hensive survey of these subsidiaries supplemented by
detailed interviews with corporate personnel in the
industry. The key drivers accounting for this growth
are then identified and explored, utilizing Tavares’s
analytical framework. Finally, some conclusions are
drawn from the foregoing analysis.
THEORIZING SUBSIDIARY EVOLUTION IN
TRANSNATIONAL COMPANIES
A considerable literature has developed in recent years
concerning the extent to which subsidiary plants of
large TNCs have experienced upgrading and evolution
(YOUNG et al., 1994; BIRKINSHAW and HOOD, 1998;
HOOD and TAGGART, 1999; TAVARES, 2001). Early
models of TNC organizational structures saw technol-
ogy and other capabilities being developed centrally
and then transferred to subsidiaries whose main function
was to supply individual national markets – what
PEARCE (1992) has termed ‘multidomestic miniature
replicas’. The high level of centralization of R&D in
particular was a function of the ‘spatial fix’ relating to
the historical development of facilities and procedures,
the economies of scale associated with centralization,
the agglomeration economies arising from embedded-
ness in rich technological milieux, efficiencies in terms
of coordinating the research effort, and avoidance of
technology leakages which would be more likely
where R&D was decentralized (EATON et al., 1994;
PEARCE, 1999a). To the extent that R&D functions
were allocated to overseas subsidiaries at all, they were
largely limited to technical support of manufacturing
operations, adaptation of products to local markets and
technical support for overseas customers (FLORIDA,
1997; RONSTADT, 1978).
However, from the 1970s on, TNC organizational
structures underwent a profound process of change in
terms of the functions performed by subsidiaries and the
nature of their relationships with their head offices,
other operating units within their parent firms and the
local environments in which subsidiaries are located.
This organizational restructuring can largely be seen as a
response to the pressures and opportunities arising from
changes in the nature of markets and the increasing
pace of technological change. Key ingredients here
were the globalization process (which both broadened
markets and intensified competition), the shortening of
product life cycles and the need for greater flexibility in
all areas of corporate activity (DUNNING, 1995;
PEARCE, 1992, 1999a). The liberalization of trade facili-
tated the rationalization of the earlier multi-domestic
system of replicated plants, some of which were closed
and others allocated specialized functions in emerging
global production systems (BIRKINSHAW and HOOD,
1998; GEREFFI, 1995; PEARCE, 1999b). This was
accompanied by an increasing tendency among TNCs
to establish or expand overseas R&D activities, driven
to a considerable extent by the desire to access, and
learn from, the technological milieux in which overseas
competitors were themselves embedded.
Many overseas subsidiaries therefore acquired new
functional mandates (basic research, product and
process development) and associated organizational
and technological capabilities which both allowed and
required them to tap into local technology knowledge
bases (CANTWELL and MUDAMBI, 1998; CANTWELL
and PISCITELLO, 2005; SCHMID and SCHURIG, 2003;
ZANFEI, 2000). Thus, where previously the function
of most overseas subsidiaries was to exploit competences
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initially developed in their home countries, new types of
creative subsidiaries emerged whose main function was
to augment home-based capabilities (CANTWELL and
MUDAMBI, 1998; KUEMMERLE, 1999). As a result,
many overseas subsidiaries came to occupy strategically
important roles, as centres of product/process develop-
ment within corporate structures in which hierarchical
layers were increasingly replaced by horizontal ‘heter-
archical’ networks (HEDLUND, 1986).
In spatial terms, the dominant feature of the growth of
high-performance TNC subsidiaries has been their con-
centration not only in countries with a strong record of
technological innovation, but also in the localized
high-technology agglomerations within these countries
which tend to be the principal sources of such innovation
(BIRKINSHAW and HOOD, 1998; CANTWELL and
PISCITELLO, 2005; KUEMMERLE, 1999). However,
there is also some evidence of functional upgrading,
including the establishment of R&D functions, at over-
seas manufacturing sites located in more peripheral
regions. Such regions commonly portray characteristics
(low skill levels, lack of physical and scientific infrastruc-
ture, supplier networks and support institutions) not
conducive to R&D activity and indeed have frequently
been the main casualties of the rationalization by TNCs
of their international structures discussed above (AMIN
and TOMANEY, 1995; DICKEN et al., 1994). However,
there are circumstances where significant development
of R&D functions, especially process R&D functions,
in peripheral branch plants has occurred.
A range of factors or drivers may have been at play.
TNCs sought to aspire to boost flexibility and the pace
of technological innovation by incorporating R&D
functions in overseas production plants: the resulting
co-location of research and production activities can be
conducive to a more efficient learning process (PEARCE,
1999a; ZANFEI, 2000). In addition, observers identify a
growing tendency for subsidiary units themselves to
acquire, or seek to acquire, a greater depth of functions
(BIRKINSHAW and HOOD, 1998; BIRKINSHAW et al.,
1998; PEARCE, 1999b). Another reason may lie in sub-
stantial investment in upgrading skill levels and scientific
infrastructures by governments of certain peripheral
regions (BIRKINSHAW and HOOD, 1998). Finally, the
lower personnel and operating costs and government
incentives (especially R&D tax credits) available in
many peripheral regions may have played a role as well
(BIRKINSHAW and HOOD, 1998, CANTWELL and
MUDAMBI, 1998; DUGA and STUDT, 2006.
PATTERSON and BROCK (2002) treat the consider-
able body of work that deals with the different factors
and processes which shape subsidiary evolution and
how these vary between subsidiaries, firms, sectors and
regions and nationalities (see also BARTLETT and
GHOSHAL, 1989; FORSGREN et al., 2000; PATTERSON
and BROCK, 2002; FROST et al., 2002; SCHMID and
SCHURIG, 2003) as a distinct stream in the subsidiary
management literature: the ‘subsidiary evolution
stream’. In this stream, the static concentration on sub-
sidiary roles that characterized the, preceding, ‘subsidiary
role stream’ (BARTLETT and GHOSHAL, 1986; WHITE
and POYNTER, 1984; D’CRUZ, 1986) was replaced by
the more dynamic development potential of subsidiaries
in host countries and an understanding of the drivers and
processes of subsidiary evolution. Authors in the subsidi-
ary evolution stream tend to adopt a more heterarchical
view of the transnational organization and accord a
greater level autonomy to the subsidiary in the evol-
utionary process. Accordingly there tends to be a
greater attention for subsidiary level factors, although
different models of subsidiary evolution emphasize
different factors depending on the perspective and
context of the researchers (BROCK, 2000).
BIRKINSHAW and HOOD (1998) provided an influ-
ential model of subsidiary evolution, emphasizing
three drivers: the parent company (decisions made by
head office managers regarding the allocation of activi-
ties), subsidiary choice and host country environment
(including support of the host government and inward
investment agencies and the strategic importance of
the country). Although the authors acknowledge that
the three mechanisms interact to determine the subsidi-
aries role, this point is not specifically developed. Based
on this model, PATTERSON and BROCK (2002) present
a more elaborate model that more specifically includes
the idea of interaction amongst the drivers. In addition,
the model recognizes the role of the global (in addition
to the host country) environment, although this is inte-
grated in the head office determinant.
TAVARES (2001, 2002), again building on the frame-
work of BIRKINSHAW and HOOD (1998), proposes an
elaborate multilevel systems perspective on subsidiary
evolution. Tavares’s analytical framework is built
around three sets of subsidiary evolution ‘drivers’:
firstly, those emanating from within subsidiaries them-
selves (for example, a desire on the part of subsidiary
managements to enhance the functions which they
perform); secondly, those deriving from the ‘internal’
environment of the TNC of which the subsidiary is a
component (for example, supports for, and blockages
to, subsidiary development emanating from the parent
firm and ‘sister’ subsidiaries); and, thirdly, those deriving
from the ‘external’ environment (Fig. 1).
Tavares adds significant embellishments to the other
models of subsidiary evolution. Tavares’s analytical fra-
mework is particularly useful in terms of her treatment
of the external environment. Firstly, unlike earlier ana-
lyses (such as BIRKINSHAW and HOOD, 1998) that
tended to equate the subsidiary’s external environment
with the host country in which it is located, Tavares
sees the external environment as operating at four differ-
ent spatial scales: the regional (micro-region), the national
(the host country), the supranational (macro-region) and
the global. Tavares also highlights the role which insti-
tutions (for example, inward investment agencies) can
play in influencing subsidiary evolution at all levels in
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this spatial hierarchy. The global external environment is
recognized as a separate driver and not introduced as part
of the headoffice driver (as in the case of PATTERSON and
BROCK, 2002).Tavares, unlikeBIRKINSHAW andHOOD
(1998), also usefully incorporates non-territorial elements
(for example, industrial competitive structure and tech-
nological change) into her conception of the external
environment. Overall, according to Tavares, the external
environment has impacted on the process of subsidiary
evolution to a much greater extent than has been
acknowledged in the existing literature. Tavares perceives
a manifest need to give greater weight to environmental
variables and argues that the most relevant influences
need not be local.
A further key element in Tavares’s analytical frame-
work is its systemic approach which, more directly
than BIRKINSHAW and HOOD (1998) and PATTERSON
and BROCK (2002), addresses the complex fabric of lin-
kages between distinct drivers. It provides for two-way
‘dialectical’ interactions between the various elements of
the subsidiary evolution system, leading to evolution
over time in the nature of these interactions. Not only
do subsidiaries interact directly with both the internal
(parent firm) and external (territorial and industrial)
environments, but also the internal and external
environments interact themselves in ways which can
impinge indirectly on subsidiaries. This can give rise to
very complex systems of interaction, the unpacking of
which can be a daunting task.
This paper utilizes Tavares’s framework to analyse the
extent of, and drivers underpinning, the incorporation of
processR&Dactivities into the subsidiaries of transnational
pharmaceutical firms operating in Ireland. However,
before addressing the findings, it next provides a descrip-
tion of the configuration of theR&Dcycle in the pharma-
ceutical industry, with particular reference to the role of
process R&D in this overall cycle, followed by an
account of the traditional spatial configuration of this cycle.
THE RESEARCH AND DEVELOPMENT
CYCLE OF THE PHARMACEUTICAL
INDUSTRY1
The pharmaceutical R&D cycle includes both the
development of new ‘active ingredients’ – also referred
to as drug substances – and the development of related
finished drug ‘formulations’ (the actual tablet, capsule
or injection through which the active ingredient is
delivered to patients). The R&D cycle entails two dis-
tinct but strongly integrated sets of activities, that is
‘product’ and ‘process’ R&D.2
The tasks of process R&D are to develop an effective
process for the large-scale manufacturing of a new drug
product and to supply material for the clinical trial
Fig. 1. Drivers of subsidiary evolution
Note: MNE, multinational enterprise. Source: TAVARES (2001)
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stages of the product R&D cycle. The process R&D
cycle involves a number of integrated activities or stages
(listed in Table 3). The cycle usually starts immediately
after candidate selection with pre-formulation studies
(where companies develop a deeper understanding of
the candidate drug and explore alternative synthetic
routes or processes). Promising routes or processes are
then progressively evaluated and scaled up via ‘paper
experiments’, computer simulation, small-scale labora-
tory experiments and experiments in the ‘kilo lab’
(a larger laboratory scale). Subsequently, the activities
move to the pilot plant where the process is further
scaled up with the research focus now on optimizing
flow rates and equipment design. Apart from developing
a manufacturing process, a second important function of
the pilot plant is to produce material for larger-scale
(Phase II and III) clinical trials.
The process R&D cycle concludes with the transfer
of drug production to commercial-scale plants which
involves final equipment design, optimization in the
commercial plant, validation, documentation of stan-
dard operating procedures and the training of operating
staff. Process development continues during the entire
life cycle of a drug in the form of continuous improve-
ment activities conducted by technical staff at the com-
mercial plant. This typically involves small, incremental,
changes that do not require re-filing with the regulatory
authorities. In addition, many companies will now start
a new cycle of process R&D for the same compound,
generally referred to as ‘second generation’. Such rede-
velopment activities, although requiring re-filing, tend
not to involve a fundamental route change.
The various stages in the process R&D cycle require
different numbers of researchers with different skill sets.
Although all stages can involve skilled and highly edu-
cated staff, the early stages in the cycle involve the great-
est number of, and the most highly skilled, researchers.
Companies generally aim to have made most major
decisions regarding the essential production process
(‘lock down’ the process) in advance of the large-scale
testing involved in Phase III clinical trials (activities 7
and 8 in Table 3). From here on, process development
focuses on the final details of the process.
The various stages of the process R&D cycle are
strongly dependent on each other and on other functions
in the pharmaceutical value chain. The initial stages of the
process R&D cycle, also referred to as process research
(activities 1–4 in Table 3), are strongly integrated with
each other as well as the discovery function in the
product R&D cycle. The pilot plant functions have
backward links with the earlier process R&D stages,
forward links with manufacturing and parallel links
with the clinical trials function in the product R&D
cycle. The post-pilot activities are all conducted at the
commercial manufacturing plants and therefore tend to
have strong linkswithmanufacturing. This has an impor-
tant influence on the spatial organization of processR&D
activity.
EARLY SPATIAL CONFIGURATION OF
PROCESS RESEARCH AND DEVELOPMENT
IN THE PHARMACEUTICALS INDUSTRY
The transnational pharmaceutical firms in the 1950s and
1960s were models of Fordist industrial organization.
R&D was typically organized as a linear process
(MALECKI, 1997; HAYTER, 1998; DICKEN, 2007).
There existed a high degree of compartmentalization of
specialized R&D functions and of separation between
R&D and manufacturing. Planned interaction between
departments was one-way and largely confined to the
moments of transfer of finished tasks. The Fordist
model involved a very distinctive geography of both
R&D and manufacturing production. The latter was
generally located away from the headquarters regions
and was frequently moved overseas, either to major
markets (especially those protected by trade barriers) or
to low-tax countries such as Ireland and Puerto Rico
where profits could be concentrated via intra-corporate
transfer pricemanipulation, a particularly important con-
sideration for the highly profitable pharmaceutical indus-
try (LALL, 1979). By contrast, until the 1980s, the R&D
functions of transnational pharmaceutical companies,
particularly the more strategic activities, remained
firmly located in their home countries, and usually in
the same regions as the head offices and main production
plants (HAYTER, 1998, HOWELLS, 1984). Some decen-
tralization of R&D did occur and branch plants fre-
quently housed small technical/development units, but
the scope of their activities was limited (HOWELLS,
1984). Even in the case of process R&D, typically, the
manufacturing process was for the most part developed
in the central R&D laboratories with the technology
then being transferred to the manufacturing division
and manufacturing sites.
However, there are indications that this geographical
configuration of process R&D is undergoing change
(along the lines identified for transnational firms gener-
ally in the second section above), characterized by a
decentralization of process R&D functions to the man-
ufacturing subsidiaries of transnational pharmaceutical
companies (CHIESA, 1996; FORFÁS, 2003; IRISH
COUNCIL FOR SCIENCE TECHNOLOGY AND INNO-
VATION (ICSTI), 2003; PISANO, 1997). This tendency
is examined further in the following section, which
focuses on the development of process R&D in the
Irish pharmaceutical industry.
PROCESS RESEARCH AND DEVELOPMENT
IN THE IRISH PHARMACEUTICAL
INDUSTRY
This section examines the extent to which the suggested
trend towards decentralization of process R&D activities
in the global networks of transnational pharmaceutical
companies is apparent among the branch plants of trans-
national pharmaceutical firms located in Ireland. It
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begins with an account of the background and growth
of the pharmaceutical industry in Ireland.
Growth of the pharmaceutical industry in Ireland
Foreign investment in the Irish pharmaceuticals industry
commenced in the 1960s following the adoption by the
Irish government of an inward investment promotion
policy (based on the availability of tax incentives,
capital grants and a plentiful supply of cheap labour) in
the late 1950s (VAN EGERAAT and BREATHNACH,
2007; VAN EGERAAT, 2006). Inward investment in the
industry accelerated in the 1970s, following Ireland’s
entry into the European Economic Community and
the implementation by the Industrial Development
Authority (IDA) of an aggressive marketing strategy
which targeted the leading companies in emerging
growth sectors, including pharmaceuticals (WHITE,
2000). This decade therefore saw a number of major
investments, mainly by US firms, in the production of
active ingredients and drug formulations (VAN
EGERAAT and BARRY, 2009).
Following a brief period of stagnation in the early
1980s, strong growth in the industry re-emerged in
the second half of the decade and has continued more
or less ever since, with employment rising from fewer
than 5000 jobs in 1985 to 20200 in 2006 (VAN
EGERAAT and BARRY, 2009). By far the strongest
growth occurred in formulation, although the active
ingredient subsector experienced significant expansion
as well, particularly in the second half of the 1990s. In
2006, subsidiaries of foreign firms accounted for 96%
of employment in the industry and 85% of plants.
Foreign plants were, for the most part, relatively large
scale (mean plant employment of 284) compared with
the more modest scale of the indigenous sector (mean
plant employment of seventy-six, with most below
fifty). Indigenous companies were mainly active in the
formulation of human and veterinary pharmaceuticals.
Process R&D activities in pharmaceutical firms in Ireland
Data sources. The analysis that follows of Ireland’s
changing role in corporate process R&D in the pharma-
ceutical industry, and of the drivers underpinning this
changing role, is based on data collected from two
sources: a set of interviews at eleven transnational
pharmaceutical companies and a mail survey of all
sixty-eight foreign-owned pharmaceutical plants in
Ireland engaged in the production of active ingredients
and/or in drug formulation.
A total of fifty-three semi-structured, face-to-face,
interviews were conducted with senior staff from
eleven major transnational pharmaceutical plants in the
period 2005–2006 (typically four to five interviews per
plant). Interviewees included generalmanagers, materials
managers, personnel managers and process development
managers.3 The selection process ensured that the sample
included (large) companies in different subsectors (drug
product and drug formulation), from different national-
ities (five US, three UK, one Swiss, one French, one
Japanese) and plants portraying different levels of invol-
vement in process R&D. The interviews focused on
obtaining a detailed understanding of the global organiz-
ation of process R&D activities in the subject firms, the
changing role of the Irish plants within these firms, as
well as the processes and the drivers involved. The inter-
view data form the basis of the discussion of the drivers of
the evolution of process R&D in the sixth section.
In addition, a mail survey was conducted of pharma-
ceutical plants in Ireland in 2006. The population of
sixty-eight pharmaceutical plants4 was based on the
annual Employment Survey of manufacturing plants in
Ireland (2006 data) conducted by Forfás (the Irish govern-
ment’sNational Policy andAdvisoryBoard for Enterprise,
Trade, Science, Technology and Innovation). The survey
generated a response rate of 94% (sixty-four useable ques-
tionnaires), covering 91% of all employees in the target
population in 2006. Table 1 presents the characteristics
of the sixty-four respondent plants. The majority of
plants are involved in drug formulation. The main
countries of origin of the respondent plants included the
United States, Germany, Britain and France (Table 2).
The main purpose of the mail survey was to quantify
the process R&D activities in the Irish pharmaceutical
industry and the relative role of the Irish subsidiaries in
the global networks of their parent firms. To get an
insight into this role, survey respondents were asked to
rate the input of the local staff in various process R&D
Table 2. Mail survey respondent plants by country of origin
Country of origin Number of respondent plants
United States 32
Germany 7
Britain 6
Japan 6
France 5
Switzerland 2
Italy 2
Other 4
Total 64
Table 1. Characteristics of survey respondent plantsa
Sample
(n)
Population
(N)
Percentage of
the population
Number of plants 64 68 94
Employment in plants 17648 19289 91
Plant type
Active ingredients 25 No data
Drug formulation 34 No data
Both active ingredients and
drug formulations
5 No data
Note: aEmployment numbers and percentages are based on Forfás
employment survey data, 2006.
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activities of the parent firm on a seven-point Likert scale.
The various categories are listed in Table 3 (for further
detail, see the fifth section). The questionnaire used in
the mail survey was, in most cases, completed by the
head of the process development unit or technical ser-
vices unit of the plants.
The scale and scope of process R&D among survey firms.
The mail survey found that in 2006 the surveyed firms
employed a total of 739 staff in process R&D. While
some of these were part of a dedicated process R&D
unit, most were employed in other functions such as
production, technical support, and quality control, and
devoted only part of their work time to process R&D
activities. Respondents were asked to estimate the pro-
portion of their time that the people involved spent on
process R&D activities. Based on this information it is
estimated that process R&D employed the equivalent
of 536 full-time people. However, the number of
staff involved varied considerably between plants:
twenty plants employed fewer than five, twenty-nine
between five and fourteen, eight between fifteen and
twenty-nine, while five plants employed thirty or more.
There had been very rapid recent growth in the
number of R&D personnel. In the six-year period
between 2000 and 2006, the number of people involved
in process R&D in the responding companies grew by
more than 140%, from 306 to 739. This compares
with a 36% growth rate in total employment in the
companies in the same period. Four-fifths of responding
plants expanded their process R&D staff in this period.
As for the future, twenty-six of the respondent plants
had concrete plans to expand their process R&D activi-
ties in Ireland over the next five years. Out of these,
twenty-three provided an estimate of the additional
process R&D staff requirements over this period,
amounting to a total of 291 additional staff.
In order to gauge the relative role of these subsidiaries
in the overall process R&D activities of their parent
firms, respondents to the mail survey were asked to
rate the input of the local staff in various process R&D
activities of the parent firm on a seven-point Likert
scale (where a score of 1 indicated that the Irish plant
had no input in the activity; and a score of 7 indicated
that the Irish plant had sole ownership of the activity
in question). This key question only applied to the
multi-site transnational firms. In addition, not all of
the categories of R&D activity included in the question
applied to all these plants. As a result, the individual
activity categories in the question applied to different
numbers of foreign plants, ranging from fifty-eight to
sixty-two. The responses are presented in Table 3,
where the activity categories are listed in descending
order in terms of their position in the process R&D
cycle sequence. In Table 3, the columns represent the
proportion of relevant plants falling into each Likert-
scale score category while the ‘Mean’ column indicates
the mean score obtained for all respondent plants for the
relevant R&D activity.
The results show that the great majority of plants (with
a small number of exceptions) have little or no involve-
ment in the early stages of the process R&D cycle (activi-
ties 1–4 in Table 3). Involvement rises somewhat for
activities 5 and 6 (production for Phase II clinical trials
and pilot plant evaluation and optimization prior to
Phase III clinical trials) but still remains generally low.
The involvement of the Irish plants only becomes sub-
stantial at Phase III clinical trials but the mean score for
the involvement in production (activity 7) is higher
than for involvement in evaluation and optimization
(activity 8). This pattern suggests (and the interviews
confirm) that in a substantial number of cases the main
function of the staff involved in process development in
Irish pilot plants is the manufacture of material to
support clinical trials. The technology staff in the plants
are generally involved in process R&D as members of
global project teams made up of staff from the R&D
and manufacturing divisions of the parent firms drawn
from different locations around the world. Such teams
are normally set up at an early stage of the process
Table 3. Involvement of Irish plants in process research and development (R&D) activities
Activity Process R&D activities
Likert-scale score (percentage of plants)a
1 2 3 4 5 6 7 Mean
1 Pre-formulation studies 74.6 6.8 0.0 1.7 5.1 3.4 8.5 2.0
2 Derivation of the initial route/process options and preliminary evaluation 71.0 11.3 1.6 3.2 6.5 1.6 4.8 1.9
3 Evaluation in small-scale experiments 63.9 13.1 3.3 3.3 4.9 1.6 9.8 2.2
4 Evaluation in the kilo lab 62.1 10.3 5.2 1.7 5.2 6.9 8.6 2.3
5 Production for Phase II clinical trials 52.8 13.2 5.7 5.7 7.5 1.9 13.2 2.6
6 Evaluation in the pilot plant prior to Phase III clinical trials 39.6 17.0 17.0 7.5 5.7 5.7 7.5 2.7
7 Production for Phase III clinical trials 25.9 5.6 9.3 9.3 14.8 16.7 18.5 4.1
8 Evaluation in the pilot plant during Phase III clinical trials 27.8 9.3 14.8 7.4 16.7 13.0 11.1 3.6
9 Equipment design 9.7 9.7 11.3 14.5 19.4 19.4 16.1 4.5
10 Optimization in a commercial plant (pre-filing) 4.8 3.2 3.2 6.5 16.1 21.0 45.2 5.7
11 Validation 0.0 0.0 3.2 4.8 6.5 22.6 62.9 6.4
12 Continuous improvement 0.0 1.6 0.0 1.6 9.7 21.0 66.1 6.5
13 Development of a second-generation process 9.8 8.2 14.8 4.9 14.8 11.5 36.1 4.9
Note: a1, No input in activity by the Irish plant; 7, Irish plant has sole ownership of activity.
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R&D cycle to facilitate early involvement in the cycle of
all the relevant functions, including manufacturing, and
to streamline the transition between the various stages
and locations. A large part of the evaluation/optimization
is carried out by staff from the process R&D groups in the
core global research locations, both at these core locations
and/or at the site in Ireland. In many cases, staff from the
Irish units, as members of the global project teams, have
some involvement in evaluation/optimization, even if
not involved in the production of the evaluation
batches. However, in most cases the involvement is
very limited, particularly at the early stages.
There is a very significant upward shift in the level of
Irish plant participation in the technology transfer phase
of the process R&D cycle – optimization in the commer-
cial plant (activity 10) and the running of validation
batches (activity 11). Technology transfer essentially
involves taking a process from the pilot plant scale and
replicating it with, preferably, minor changes at the com-
mercial manufacturing plant. This activity is typically
organized through commissioning teams that include
staff from the transferring location and, on the receiving
end, local staff with responsibility for new product intro-
ductions.Once the commercial manufacturing plant is up
and running, continuous improvement activities (activity
12) tend to be carried out almost entirely by local staff. At
this stage staff from the core research locations tend to
have a very limited, more consultative, role.
Overall the mail survey data clearly show that the
involvement of the Irish staff in process R&D only
becomes substantial after the proof-of-concept point, at
the start of Phase III clinical trials. As pointed out in the
outline of the process R&D cycles, this is the point at
which companies generally want to have locked down
the process parameters. From here on process R&D
activities focus on the final details of the process and tech-
nology transfer.
The fact that the Irish plants tend to concentrate their
involvement in process R&D activities in the later stages
of the cycle does not mean that they are involved in
low-skill activities. The mail survey shows that the
process R&D activities employ a substantial number of
highly skilled people, with 30% of the 739 people
involved holding a doctorate as their highest level of
academic attainment, with 18% having a master’s
degree, and a further 46% a primary degree.
Having outlined the specific nature of the process
R&D activities which have recently been decentralized
to the Irish operations, the paper now turns to an analy-
sis of the factors that have driven this tendency to
decentralize.
THE DRIVERS OF THE EVOLUTION IN
PROCESS DEVELOPMENT ACTIVITIES IN
IRISH PHARMACEUTICAL SUBSIDIARIES
In analysing the drivers of process R&Ddecentralization,
this section employs the analytical framework proposed
by TAVARES (2001) which distinguishes between
drivers operating in the external environment, those
operating in the internal environment (that is within
the parent corporation), and those emanating from
within the Irish subsidiaries themselves, while at the
same time emphasizing the fact that the different
drivers act in a systemic way, involving processes of
mutual interaction, reinforcement and co-evolution.
The following subsections are organized so as to high-
light the interactions between drivers. Most of the
described interactions involve the external environment.
Tavares sees external drivers as operating at four spatial
scales: the global, the (supranational) macro-regional,
the national (host country), and the (sub-national)
micro-regional. Given the relatively small size of
Ireland, the micro-regional scale was deemed to be of
limited significance for the evolution of process R&D
activities and is not integrated in the analysis.
Changes in the global competitive and technological environment
leading to a focus on efficiency in process R&D (global external
environment–internal environment interaction)
Since the 1980s pharmaceutical companies have been
increasingly confronted by major, global, changes in
their competitive, regulatory and technological environ-
ments. Many of these changes had an impact on the cor-
porate strategy (internal environment), including on the
way companies organized and spatially configured the
process development function.
The combination of increasingly stringent regulatory
requirements, the concomitant reduction of the effective
period in which a product enjoys patent protection
(HOWELLS et al., 2005; PISANO, 1997), greater complex-
ity of new product and process technologies (PISANO,
1997), higher levels of competition due to the emergence
on new biotechnology firms and the introduction of
price controls by governments (AGRAWAL, 1999) has
substantially increased the costs and reduced the revenues
of pharmaceutical companies.
These developments in their external environment
spurred pharmaceutical companies to review their cor-
porate strategies and organizational configurations. A
key target of this review process has been the inefficien-
cies in the Fordist organization of R&D and production.
The compartmentalization of specialized R&D func-
tions, the separation between R&D and manufacturing,
and the one-way interaction between departments
involved a lot of wastage, high costs and long develop-
ment times (HAYTER, 1998).
The review resulted in widespread restructuring of
the way the TNCs configure their global process
R&D operations. This reorganization is designed to
reduce not only the cost of developing and manufactur-
ing new products, but also, more importantly, the time
it takes to bring new products to the market, thereby
increasing the effective patent protection period
(PISANO, 1997). One of the key themes in the
1160 Chris van Egeraat and Proinnsias Breathnach
D
ow
nl
oa
de
d 
by
 [M
ay
no
ot
h 
U
ni
ve
rs
ity
 L
ib
ra
ry
] a
t 0
6:
27
 2
5 
M
ay
 2
01
5 
reorganization of process R&D is ‘coordination inte-
gration’, involving better integration between both
the various stages of the process R&D cycle and the
product discovery, process development and manufac-
turing functions.
This increase in the degree of coordination inte-
gration and the concomitant requirement for improved
communication flows can explain, at least in part, the
rise in the level of process development activities in
Irish pharmaceutical manufacturing subsidiaries in
recent years. PISANO (1997) suggests that coordination
between process R&D and manufacturing is best facili-
tated through the co-location of these functions, which
previously tended to be separated. However, the idea of
co-location of process R&D and manufacturing is com-
plicated by the fact that transnational firms generally
operate multiple manufacturing plants around the
world. In this context co-location can lead to fragmen-
tation of the process R&D function, and the impairment
of information flow within the overall corporate R&D
organization (MALECKI, 1997). Location decisions
regarding (individual) process development functions
relative to other functions necessarily involve a trade-
off between these conflicting considerations.
This trade-off is reflected in the organization and
spatial configuration of the process development activi-
ties of the surveyed companies. The interviews all con-
firmed a strong emphasis on coordination between the
process development and manufacturing functions.
Process development project teams involve members
from various organizations, including discovery,
process R&D and commercial manufacturing. The
coordination involves a large amount of information
exchange, including face-to-face exchange. In relation
to the pilot plants, the interviewees generally confirmed
that co-location with the commercial manufacturing
plants in Ireland did facilitate information exchange,
particularly when technology was being transferred to
the latter plants. At the same time, invariably, the
early-stage process R&D functions remain strongly cen-
tralized in the core global research locations, partly to
facilitate communication with the centralized discovery
groups and partly to achieve economies of scale. In fact,
a large part of the actual process R&D work in the Irish
pilot plants is carried out by staff from central process
development groups. Strongly developed organizational
links and advanced information and communication
technology infrastructure between the core process
development locations and the staff at the pilot plants
reduces the requirement for travel to an extent. As
one pilot plant manager mentioned:
We have learned that telecommunications are extremely
effective. Once you establish a relationship face-to-face,
you can maintain that very effectively. […] We don’t
even use the video anymore. Telephone is fine. We use
the video system for data display. We find that to be
hugely valuable. We can edit documents on line
(Manager of an active ingredient pilot plant, 2006)
Still, centrally located staff need to travel regularly to
carry out the process development and technology
transfer work in conjunction with staff based at the
local facilities. Hence, at least some of the gain in effi-
ciency in face-to-face information exchange between
the pilot plant and the commercial plant comes at the
expense of a higher amount of travel between the
pilot plant in Ireland and the process development
groups in the core locations.
Co-locating pilot plants at commercial plants in
Ireland streamlines the technology transfer to the com-
mercial plant in other important ways as well. Firstly, it
can significantly speed up the regulatory process in that,
in order to register a production process, batches pro-
duced at the pilot plant need to be inspected by the regu-
latory authorities. If this pilot plant is located at the same
site as the commercial plant, registration of the process
will qualify the entire site, including the commercial
plant. This significantly shortens the length of the
overall registration process. Finally, co-location of the
pilot and commercial plants also facilitates post-launch
continuous improvement and process redevelopment
(second-generation) activities. Typically, a large part of
these activities is carried out by themanufacturing organ-
ization and its staff located at the commercial plants. Since
their work can require experimentation in the pilot
plants, co-location provides obvious efficiencies.
To quantify the relative importance of possible
reasons for locating process R&D activities in Ireland,
the respondents at subsidiaries with process develop-
ment units were asked to rate a set of possible reasons
on a five-point Likert scale. Six key reasons were ident-
ified (Table 4). The desire to have process R&D located
near the manufacturing plant to support the efficiency of
the process development trajectory was clearly the most
important factor (with an average score of 4.3). This was
followed, in descending order of importance, by: the
efforts of the government to increase the value added
of the local operations; the desire of local management
to increase the profile of the operations; the relative
availability of skilled labour; the desire to tap in the
local skills base; and the lower cost of skilled labour in
Ireland. The interviewees were in most cases not in a
position to score the role of the international taxation
regime. These reasons will be discussed in the following
sections.
Global competitive environment and market liberalization leading
to consolidation of plants (global and supranational external
environment–internal environment interaction)
Changes in the global competitive and technological
external environment also stimulated process develop-
ment activities by changing the relative size of the Irish
manufacturing operations. This was driven by two
factors. The first of these was a wave of merger and
acquisition activity which occurred in the global
pharmaceutical industry in the 1990s – itself a response
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to the growing global competitive pressures being
experienced in the industry at the time (AGRAWAL,
1999). A common consequence of these mergers and
acquisitions was the rationalization of excess manufac-
turing capacity (SCHOFIELD, 2001). Secondly, the
Single European Market and the ongoing World
Trade Organisation negotiations have greatly reduced
the necessity to operate duplicate drug product plants
in different national markets, as had previously been
the norm in the pharmaceutical industry (SCHWEITZER,
1997; GAMBARDELLA et al., 2000). A number of compa-
nies responded to this change in their external environ-
ment by rationalizing their manufacturing plants on a
European or even global scale. Both dynamics have
lead to a concentration of manufacturing capacity in
fewer and larger plants or ‘super-manufacturing’ facilities
(ICSTI, 1999).
For reasons mainly related to its (long-) established
corporate taxation regime, Ireland was an attractive
location for the consolidated facilities which emerged
from this rationalization process, with the result that
many pharmaceutical subsidiaries in Ireland became
the largest manufacturing sites in their corporate net-
works (VAN EGERAAT and BARRY, 2009). An increas-
ing number of these plants now act as ‘strategic sites’
responsible for global new product launches. As a
result, the Irish sites became prime targets for the reloca-
tion of process development activity arising from the
new organizational structures described above. To give
an example, one of the respondent plants was established
in the early 1990s to consolidate the formulation activi-
ties of thirteen existing European manufacturing plants.
At the time of the interview a new pilot plant had been
added to the site and a substantial process development
unit had been established, employing forty-five staff and
a further expansion of this group, involving a further
forty staff, had been announced.
Again the initial impetus for subsidiary evolution ori-
ginated in the general changes in the external operating
environment but was channelled through the internal
environment of the parent company to the benefitting
subsidiaries.
Changes in the taxation regime leading to corporate decisions to
locate pilot plants in Ireland (global external environment–internal
environment interaction)
A third instance of change in the external environment
which has operated through the internal corporate
environment to stimulate the location of process R&D
in the Irish subsidiaries is related to the (international)
tax regime within which pharmaceutical TNCs
operate. At first glance, Ireland’s low corporation tax
should work against TNCs carrying out R&D activities
in Ireland, as TNCs generally prefer to undertake R&D
in high-tax regimes so that R&D expenditure can be
written off against higher rates of corporation tax,
thereby reducing the global tax bill (ICSTI, 1999,
2003). The attraction of the United States as a location
for R&D is further enhanced by relatively generous tax
allowances for R&D expenses.
However, interviews with staff at international
accountancy firms and material from existing studies
(MUTTI and GRUBERT, 2007) suggest that develop-
ments in other aspects of international and national taxa-
tion regimes, notably those related to intellectual
property (IP), have actively encouraged the location of
process R&D in Ireland.
The key event in this respect was the introduction, in
the mid-1990s, of US legislation for Cost-Sharing
Arrangements (CSAs) which permits companies in
different jurisdictions to share the R&D costs involved
in developing IP. Because the costs are shared, the rev-
enues and profits arising from the development of IP
may also be shared. This provides an instrument
which allows TNCs to shift some profits to subsidiaries
(registered as separate companies) in jurisdictions (such
as Ireland) where corporation tax rates are lower than
in the United States, thereby facilitating a significant
reduction in the global effective tax rate for the TNC
in question.
Typically a CSA involves a buy-in payment where
the Irish subsidiary pays the parent company for the
value of the pre-existing IP. In theory this buy-in
payment should be a fair reflection of the value of the
IP transferred. However, the system is susceptible to
abuse and pharmaceutical firms are widely believed to
undervalue the buy-in payments. This is supported by
the creation of complex global administrative structures
and the location of functions additional to manufactur-
ing, including R&D, in low-tax jurisdictions such as
Ireland. The presence of such R&D facilities can be
used to justify inflated levels of IP, value added and
profits attributed to the Irish subsidiaries. A common
justification device is the involvement of Irish subsidi-
aries in the development of second generations of exist-
ing products (see also MUTTI and GRUBERT, 2007;
SIMPSON, 2005; THE IRISH TIMES, 2006).
Table 4. Reasons for locating a process development unit in
Irelanda
Mean Likert-scale
scoreb
Desire to have process research and develop-
ment located near manufacturing plant
4.3
Desire to tap into local skills base (quality) 2.9
Lower cost of skilled labour 1.8
Relative availability of skilled labour 2.9
Desire of local management/staff to increase the
profile of the operations
3.0
Efforts of the Irish government to increase the
value added of the local operations
3.2
Notes: aInterviewees were in many cases not in a position to score the
role of the international tax regime.
bMean score on a five-point Likert scale: 1, factor played no
role; 5, factor played a crucial role.
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These developments illustrate the systemic nature of
the processes and the co-evolution of the drivers
involved in subsidiary evolution. On the one hand,
these developments can be interpreted as ‘the multina-
tional shifting governance modes and structures in
response to environmental shocks’ (TAVARES, 2001,
p. 146). On the other hand, the environmental shock
was, to an extent, the outcome of lobbying on the part
of the TNCs.
This research was unable to quantify the relative
importance of the international tax regime because
interviewees at local subsidiary level were in many
cases not in a position to score the role of this regime.
But the comments of the vice-president of one of the
respondent companies, located at the global headquar-
ters, were revealing. After discussing the details of the
international taxation regime and its influence on the
location of the pilot plant in Ireland, he summarized
the situation as follows:
the synergies are the main drivers, but the other driver is
tax advantages. […] So there is synergies, there is the regu-
latory issue and there is tax.
To the interviewer’s question which factor weighed
strongest, the answer was unambiguous: ‘Tax.’
In reaction to the changes in the global external and internal
environments, host country policies enhance the attractiveness of
Ireland (global external–internal–national–external interactions)
The majority of plans for the establishment or major
expansions of process R&D units originated in the
‘internal environment’ (mainly instigated by changes in
the global competitive and technological environment
and in the international taxation environment). To
what extent have developments in the national external
environment (the host country) played a role or influ-
enced these plans and related location decisions, and
how do these developments interact with other drivers?
Ireland’s technological system in the area of pharma-
ceuticals has not been particularly attractive to TNCs
investing in R&D units. However, in recent years,
partly in reaction to the new opportunities offered by
the increasing internationalization of R&D functions
by TNCs, the Irish government implemented a range
of measures to upgrade the local factor conditions and
stimulate value-adding activities in the pharmaceutical
industry.
The supply of science and technology graduates and
high-level science researchers grew rapidly in the 1990s,
partly due to increased government investment in edu-
cation. Between 1993 and 2004, the annual output of
science and technology graduates from the higher edu-
cation system grew by 50% (calculated from data given
in DUFF, 2007). The research infrastructure received a
further boost through a substantial increase in funding
of research institutions and research projects. Finally,
several tax-relief and grant measures have been
introduced with the specific objective of promoting
R&D and innovation in foreign-owned branch plants.
A large share of the new resources has been used to
support the pharmaceutical/biotechnology sector,
which has been identified as possessing considerable
potential for future growth. For example, Science
Foundation Ireland (SFI), in its first three years of oper-
ation, allocated 40% of its €550 million basic research
fund to research in biosciences and bioengineering
(SFI, 2006). Cognisant of the above-mentioned
changes in the global ‘external’ and corporate ‘internal’
environments, Irish industrial policy documents specifi-
cally promoted process R&D as an important area for
higher value-added activity (ICSTI, 2003; ENTERPRISE
STRATEGY GROUP, 2004). In line with this, in 2006 the
technology infrastructure for pharmaceutical process
R&D was significantly expanded with the establishment
of the government-funded National Institute for
Bioprocessing Research and Training – a centre of
excellence for the Irish bioprocessing industry.
In relation to the availability of skilled workers, the
Likert-scale scores (Table 4) suggest that the relative
availability of skilled labour and the increased quality
of the research skills of graduates in the Irish labour
pool has exerted a limited positive influence on the
decisions to locate process development units in
Ireland (a mean score of 2.9 on a five-point Likert
scale). However, evidence from the actual discussions
suggests that the attraction lies in the availability rather
than in the quality of the graduates and that the really
high-end skills remain in short supply.
Relative availability was probably a big driver and it still
probably is relative to other countries. I think the biggest
challenge is that we need to get the right skills coming
forward. And I don’t think the academic institutions necess-
arily understand what the right skills are. […] I think the
process engineering in Ireland historically has been about
going out and working in a manufacturing plant. We are
not developing process engineers with PhDs and with fun-
damental scientific focus. […] The universities are very old-
fashioned, with test tubes. They are behind the times you
know. […] Coming out of Ireland the PhDs tend to be
too narrow. They are not broad enough.
(Director of an active ingredient pilot plant, firm 10, 2006)
We don’t have an oversupply of suitable employees. So
when we recruited for the unit, day one we brought in
a lot of people from France and the UK. […] So really,
because there is so little R&D in Ireland to start with,
we were not able to poach it of people. […] I think
there is not enough of a focus in [the education system
of] Ireland. It is engineering, and the tech transfer and
the running of the process. We are looking here at a lot
more creative synthetic chemistry, quite a big emphasis
on learning. So we are finding it a bit of a challenge [to
find staff with suitable skills].
(Manager of a process development centre, firm 5, 2006)
This suggests that, in relation to education and skills, the
Irish national environment is trailing the growing
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requirements of pharmaceutical subsidiaries located in
Ireland. This in turn suggests that, although the expan-
sion and upgrading of the skills pool has served to
enhance Ireland’s attractiveness as a base for process
R&D functions, and has facilitated the greater role of
subsidiaries in process R&D, the instigating drivers for
the greater involvement of Irish subsidiaries in process
R&D reside primarily in the global and macro-regional
external environment and the related corporate
response (internal environment).
As regards the upgrading of the pharmaceutical
research infrastructure, this upgrading is of relatively
recent origin and certainly played no role in relation
to the process development units which were estab-
lished during the 1990s. However, two interviewees
suggested that it positively influenced recent invest-
ments in process development activity.
Finally, Table 4 shows that other efforts by the Irish
government to increase the value added of the local oper-
ations of foreign pharmaceutical plants played a positive
role as well, receiving an average score of 3.2. Intervie-
wees typically mentioned the grants supplied by the
industrial development agencies and, often in the same
breath, the supporting role of the IDA in general.
Nearly all process R&D projects had received govern-
ment funding. Several interviewees also corroborated
AMIN and TOMANEY’s (1995) very positive assessment
of the role played by the IDA, which often had a direct
involvement in the development of grant applications.
Subsidiary management proposes process R&D projects to cor-
porate headquarters (internal environment–subsidiary interaction)
The subsidiary evolution literature tends to give much
attention to subsidiary-level factors (PATTERSON and
BROCK, 2002) and these factors are generally seen as
the main driver. In support of TAVARES (2001), this
clearly was not the case in the context of the Irish
pharmaceutical industry. The highly regulated nature
of process development in the pharmaceutical industry
strongly restricts the room for autonomous development
of initiatives by ‘entrepreneurial’ local subsidiary man-
agement. This is not to say that the local subsidiaries
play no role in driving their own evolutionary process.
The company interviews identified a small number of
projects that started on the initiative of the Irish subsidi-
ary. In these cases the projects depended strongly on the
quality and energy of local staff. One interviewee even
gave evidence of the need to overcome ‘structural
inertia’ at the parent company level (TAVARES, 2001).
It took quite a while to convince people [to establish the
local pilot plant]. The biggest barrier was that we already
had a pilot plant in our organization. So why build a
new one in Ireland.
(Director of an active ingredient pilot plant, firm 10, 2006)
In addition to a desire to improve the efficiency of the
process development trajectory and plant performance
through the attraction of a process R&D function, the
interviews suggest that local subsidiary management is
also driven, in some cases, by motives linked to inter-
subsidiary competition and personal career advance-
ment. The desire of local management/staff to enhance
the profile of the Irish subsidiary within the corporation
received a mean score of 3.0 on the five-point Likert
scale. Such enhancement is deemed important for the
long-term survival of the subsidiary in the face of corpor-
ate consolidation activities and rising factor costs in
Ireland. Local technology staff are also driven by the
desire to be involved in more advanced and challenging
activities. One manager of a technology group in a plant
with a limited process development remit put it as
follows:
We have highly educated skilled professionals working in
the department and all we want is a crack at it. It can be a
bit frustrating.
(Manager of a process technology group, drug product
plant, firm 8, 2006)
These examples illustrate that the local subsidiary
driver does interact and influence the internal (corpor-
ate) environment and that this played some role in the
evolution of the pharmaceutical subsidiaries. Neverthe-
less, it is clear from the interviews that the main impetus
behind the majority of establishments or major expan-
sions of process R&D units in the survey firms origi-
nated from within the internal environment (the
parent), mainly driven, in turn, by developments in
the global external environment. The first quote also
pertinently illustrates how the evolution of the local
subsidiary can be influenced by the activities of sister
subsidiaries.
CONCLUSIONS
This paper has found that vigorous growth is occurring
in the incidence of process R&D activity among manu-
facturing subsidiaries of transnational pharmaceutical
firms located in Ireland. While this activity is concen-
trated in the less skill-intensive later stages in the
process R&D cycle, it has nevertheless involved a sub-
stantial upgrading in skill levels in the plants concerned.
In examining the drivers responsible for this evol-
ution, the analytical framework proposed by TAVARES
(2001) proved to be fruitful. Themodel’s embellishments
to other models for subsidiary evolution (BIRKINSHAW
and HOOD, 1998; PATTERSON and BROCK, 2002) are
pertinent. Almost all the categories and subcategories of
drivers identified by Tavares were found to be influential
in the Irish case, with Irish subsidiary upgrading arising
from a combination of impulses deriving from the exter-
nal environment, the internal corporate environment of
the parent firms of Irish subsidiaries, and the subsidiaries
themselves. Furthermore, the external drivers were
seen to operate at different spatial scales, as proposed by
Tavares, including the global/industrial (new regulatory,
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technological and competitive contexts), the macro-
regional (in the formof rationalization processes resulting
from the creation of the Single EuropeanMarket) and the
host-country (Irish government measures to stimulate
industrial development in general and functional upgrad-
ing in particular) levels. The findings show that the
primary drivers for the subsidiaries’ enhanced role in
process R&D lie in the external environment, notably
at the global/industrial level. This supports Tavares’s
contention that greater weight needs to be given to
environmental drivers of subsidiary evolution and that
the most relevant influences need not be local. If sup-
ported by future studies, this finding calls for a softening
of the focus on local factors which dominates the current
regional studies literature.
A particularly insightful element of Tavares’s frame-
work for subsidiary evolution – its systemic nature,
whereby various drivers mutually interact, co-evolve
and operate through each other to influence subsidiary
evolution – was seen to work to particular effect in the
Irish case. For example, the changes in the internal
organization of R&D within pharmaceutical firms
which favoured the transfer of process R&D functions
to Irish subsidiaries were themselves driven by the need
on the part of these firms to respond to key develop-
ments in their global/industrial external environments.
At the same time, some of the changes in the external
environment were partly influenced by actions in the
internal environment, as in the case of the introduction
of US legislation for cost-sharing arrangements and the
Irish governments’ efforts to upgrade the local factor
conditions.
Ultimately, the significant upgrading that has
occurred in the process R&D functionality of Irish
pharmaceutical subsidiaries has arisen largely from devel-
opments in the global external environment which have
proved serendipitous for Ireland; initiatives undertaken
by the Irish government and the Irish subsidiaries them-
selves have only been of secondary significance in this
context. This points to the contingent nature and
inherent fragility of the Irish industrial structure, domi-
nated as it is by subsidiary operations of transnational
firms.
The findings highlight opportunities and challenges
for Ireland in its pursuit of process R&D functions in
the pharmaceutical industry. On the one hand there is
great opportunity for the expansion of activities in the
final stages of the process R&D cycle either through
the establishment of new process R&D units or in the
form of expansion of staff numbers at existing units.
The findings suggest that this, in itself, requires further
efforts to expand and upgrade the national pool of
workers with relevant process development skills. On
the other hand, serious challenges remain in relation
to the upstream phases of the process R&D cycle. In
the short-term the Irish government’s latitude to
stimulate these upstream phases is limited. Corporations
will prove very reluctant to move such activities away
from their core product R&D units and it is question-
able whether such upstream process R&D activities
can be developed in Ireland without the parallel devel-
opment of a product R&D infrastructure. This will not
prove an easy task given the fact that the product R&D
functions of transnational companies are becoming
increasingly concentrated in a small number of global
innovation ‘megacentres’ and, as yet, Ireland is not
close to joining this league (VAN EGERAAT and
BARRY, 2009).
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NOTES
1. The R&D cycle of the pharmaceutical industry is very
complex. This section confines itself to presenting a
concise overview of this cycle, and to highlighting certain
aspects of the cycle which are particularly germane to the
empirical part of the paper and the associated arguments
regarding the drivers of subsidiary evolution. For a more
detailed description of the pharmaceutical R&D cycle,
see VAN EGERAAT (2010). This section is partly based on
PISANO (1997) supplemented with information obtained
during company interviews.
2. The product R&D cycle can be divided into four stages:
initial drug discovery, preclinical development, clinical
development and regulatory approval. The discovery
stage is concerned with research into the causes of diseases
and the identification of compounds that could be active in
relation to the treatment of certain diseases. Compounds
that offer most potential (drug candidates) are then tested
on animals in the preclinical development stage, with
any candidate which emerges successfully from this stage
entering the clinical development stage, during which
the drug is tested on humans. This stage generally involves
three phases, during which the drug is tested on increas-
ingly large groups of human subjects. Successful Phase II
trials can lead to the drug candidate achieving what is
termed ‘proof of concept’ status, which sanctions the com-
mencement of the costly Phase III trials, where the drug is
tested on thousands of patients.
3. In addition to these interviews at subsidiary level, two inter-
views were conducted at the global headquarters of two of
the respondent firms as well as with staff at the Industrial
Development Agency, The Irish PharmaChemical
Association and two international accountancy firms with
specialist knowledge of the industry.
4. By ‘plant’ the authors refer to single plant operations as
well as to sites with multiple plants, but operating as one
subsidiary or branch.
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